[1]
Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet (London, England). 2017 Nov 11:390(10108):2183-2193. doi: 10.1016/S0140-6736(17)31469-1. Epub 2017 May 31
[PubMed PMID: 28577860]
[2]
Zias J, Stark H, Sellgman J, Levy R, Werker E, Breuer A, Mechoulam R. Early medical use of cannabis. Nature. 1993 May 20:363(6426):215
[PubMed PMID: 8387642]
[3]
Murillo-Rodríguez E. The role of the CB1 receptor in the regulation of sleep. Progress in neuro-psychopharmacology & biological psychiatry. 2008 Aug 1:32(6):1420-7. doi: 10.1016/j.pnpbp.2008.04.008. Epub 2008 Apr 18
[PubMed PMID: 18514375]
[4]
Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of pain and symptom management. 2010 Feb:39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008. Epub 2009 Nov 5
[PubMed PMID: 19896326]
Level 1 (high-level) evidence
[5]
Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clinical therapeutics. 2007 Sep:29(9):2068-79
[PubMed PMID: 18035205]
[6]
Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005 Sep 27:65(6):812-9
[PubMed PMID: 16186518]
Level 1 (high-level) evidence
[7]
Mounessa JS, Siegel JA, Dunnick CA, Dellavalle RP. The role of cannabinoids in dermatology. Journal of the American Academy of Dermatology. 2017 Jul:77(1):188-190. doi: 10.1016/j.jaad.2017.02.056. Epub 2017 Apr 14
[PubMed PMID: 28416341]
[8]
Miller S, Daily L, Leishman E, Bradshaw H, Straiker A. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. Investigative ophthalmology & visual science. 2018 Dec 3:59(15):5904-5911. doi: 10.1167/iovs.18-24838. Epub
[PubMed PMID: 30550613]
[9]
Merritt JC, Perry DD, Russell DN, Jones BF. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. Journal of clinical pharmacology. 1981 Aug-Sep:21(S1):467S-471S
[PubMed PMID: 6271841]
[10]
Amin MR, Ali DW. Pharmacology of Medical Cannabis. Advances in experimental medicine and biology. 2019:1162():151-165. doi: 10.1007/978-3-030-21737-2_8. Epub
[PubMed PMID: 31332738]
Level 3 (low-level) evidence
[11]
Porcella A, Maxia C, Gessa GL, Pani L. The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. The European journal of neuroscience. 2000 Mar:12(3):1123-7
[PubMed PMID: 10762343]
[12]
Murataeva N, Miller S, Dhopeshwarkar A, Leishman E, Daily L, Taylor X, Morton B, Lashmet M, Bradshaw H, Hillard CJ, Romero J, Straiker A. Cannabinoid CB2R receptors are upregulated with corneal injury and regulate the course of corneal wound healing. Experimental eye research. 2019 May:182():74-84. doi: 10.1016/j.exer.2019.03.011. Epub 2019 Mar 21
[PubMed PMID: 30905716]
[13]
Lu Q, Straiker A, Lu Q, Maguire G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Visual neuroscience. 2000 Jan-Feb:17(1):91-5
[PubMed PMID: 10750830]
[16]
Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980 Mar:87(3):222-8
[PubMed PMID: 7053160]
[17]
Cooler P, Gregg JM. Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans. Southern medical journal. 1977 Aug:70(8):951-4
[PubMed PMID: 329423]
[18]
Tiedeman JS, Shields MB, Weber PA, Crow JW, Cocchetto DM, Harris WA, Howes JF. Effect of synthetic cannabinoids on elevated intraocular pressure. Ophthalmology. 1981 Mar:88(3):270-7
[PubMed PMID: 7015221]
[19]
Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. Journal of glaucoma. 2006 Oct:15(5):349-53
[PubMed PMID: 16988594]
Level 3 (low-level) evidence
[20]
Adelli GR, Bhagav P, Taskar P, Hingorani T, Pettaway S, Gul W, ElSohly MA, Repka MA, Majumdar S. Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. Investigative ophthalmology & visual science. 2017 Apr 1:58(4):2167-2179. doi: 10.1167/iovs.16-20757. Epub
[PubMed PMID: 28399267]
[21]
Porcella A, Maxia C, Gessa GL, Pani L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. The European journal of neuroscience. 2001 Jan:13(2):409-12
[PubMed PMID: 11168547]
[22]
Green K, Roth M. Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man. Archives of ophthalmology (Chicago, Ill. : 1960). 1982 Feb:100(2):265-7
[PubMed PMID: 6279061]
[23]
Chien FY, Wang RF, Mittag TW, Podos SM. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Archives of ophthalmology (Chicago, Ill. : 1960). 2003 Jan:121(1):87-90
[PubMed PMID: 12523891]
[24]
Porcella A, Casellas P, Gessa GL, Pani L. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. Brain research. Molecular brain research. 1998 Jul 15:58(1-2):240-5
[PubMed PMID: 9685662]
Level 3 (low-level) evidence
[25]
Hommer N, Kallab M, Szegedi S, Puchner S, Stjepanek K, Bauer M, Werkmeister RM, Schmetterer L, Abensperg-Traun M, Garhöfer G, Schmidl D. The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial. Clinical pharmacology and therapeutics. 2020 Jul:108(1):155-161. doi: 10.1002/cpt.1797. Epub 2020 Feb 23
[PubMed PMID: 31977076]
Level 1 (high-level) evidence
[26]
Plange N, Arend KO, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A, Huth J, Sponsel WE, Remky A. Dronabinol and retinal hemodynamics in humans. American journal of ophthalmology. 2007 Jan:143(1):173-4
[PubMed PMID: 17188063]
[27]
Green K, Wynn H, Padgett D. Effects of delta9-tetrahydrocannabinol on ocular blood flow and aqueous humor formation. Experimental eye research. 1978 Jan:26(1):65-9
[PubMed PMID: 624325]
[28]
Crandall J, Matragoon S, Khalifa YM, Borlongan C, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma. Ophthalmic research. 2007:39(2):69-75
[PubMed PMID: 17284931]
[29]
Nucci C, Gasperi V, Tartaglione R, Cerulli A, Terrinoni A, Bari M, De Simone C, Agrò AF, Morrone LA, Corasaniti MT, Bagetta G, Maccarrone M. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Investigative ophthalmology & visual science. 2007 Jul:48(7):2997-3004
[PubMed PMID: 17591864]
[30]
Pinar-Sueiro S, Zorrilla Hurtado JÁ, Veiga-Crespo P, Sharma SC, Vecino E. Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat. Experimental eye research. 2013 May:110():55-8. doi: 10.1016/j.exer.2013.02.009. Epub 2013 Feb 20
[PubMed PMID: 23454099]
[31]
Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision research. 1997 Dec:37(24):3483-93
[PubMed PMID: 9425525]
[32]
Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Investigative ophthalmology & visual science. 1996 Jul:37(8):1618-24
[PubMed PMID: 8675405]
[33]
El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, Roon P, Caldwell RB, Caldwell RW, Green K, Liou GI. Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. The American journal of pathology. 2003 Nov:163(5):1997-2008
[PubMed PMID: 14578199]
[34]
Krishnan G, Chatterjee N. Endocannabinoids alleviate proinflammatory conditions by modulating innate immune response in muller glia during inflammation. Glia. 2012 Nov:60(11):1629-45. doi: 10.1002/glia.22380. Epub 2012 Jul 17
[PubMed PMID: 22807196]
[35]
Kim SH, Kim JY, Kim DM, Ko HS, Kim SY, Yoo T, Hwang SS, Park SS. Investigations on the association between normal tension glaucoma and single nucleotide polymorphisms of the endothelin-1 and endothelin receptor genes. Molecular vision. 2006 Aug 29:12():1016-21
[PubMed PMID: 16971893]
[36]
Lucas A, Thirion A, Schwan R, Krieg J, Angioi-Duprez K, Laprevote V, Schwitzer T. Association between increased retinal background noise and co-occurrent regular cannabis and alcohol use. Progress in neuro-psychopharmacology & biological psychiatry. 2019 Mar 8:89():335-340. doi: 10.1016/j.pnpbp.2018.10.002. Epub 2018 Oct 5
[PubMed PMID: 30292729]
[37]
Schwitzer T, Henrion ML, Sarre D, Albuisson E, Angioi-Duprez K, Giersch A, Lalanne L, Schwan R, Laprevote V. Spatial localization of retinal anomalies in regular cannabis users: The relevance of the multifocal electroretinogram. Schizophrenia research. 2020 May:219():56-61. doi: 10.1016/j.schres.2019.01.013. Epub 2019 Jan 26
[PubMed PMID: 30696610]
[38]
Schwitzer T, Schwan R, Albuisson E, Giersch A, Lalanne L, Angioi-Duprez K, Laprevote V. Association Between Regular Cannabis Use and Ganglion Cell Dysfunction. JAMA ophthalmology. 2017 Jan 1:135(1):54-60. doi: 10.1001/jamaophthalmol.2016.4761. Epub
[PubMed PMID: 27930757]
[39]
Schwitzer T, Robert MP, Giersch A, Angioi-Duprez K, Ingster-Moati I, Pon-Monnier A, Schwan R, Laprevote V. Transient Retinal Dysfunctions after Acute Cannabis Use. European addiction research. 2016:22(6):287-291
[PubMed PMID: 27376753]
[40]
Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clinical kidney journal. 2013 Jun:6(3):330-3. doi: 10.1093/ckj/sft047. Epub
[PubMed PMID: 26064495]
[41]
Zawatsky CN, Abdalla J, Cinar R. Synthetic cannabinoids induce acute lung inflammation via cannabinoid receptor 1 activation. ERJ open research. 2020 Jul:6(3):. pii: 00121-2020. doi: 10.1183/23120541.00121-2020. Epub 2020 Aug 17
[PubMed PMID: 32832534]
[42]
Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. British journal of clinical pharmacology. 2018 Nov:84(11):2477-2482. doi: 10.1111/bcp.13710. Epub 2018 Aug 7
[PubMed PMID: 30001569]
[43]
Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction (Abingdon, England). 1997 Mar:92(3):279-96
[PubMed PMID: 9219390]
[44]
Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001 Nov:56(11):1059-68
[PubMed PMID: 11703238]
[45]
Sridhar KS, Raub WA Jr, Weatherby NL, Metsch LR, Surratt HL, Inciardi JA, Duncan RC, Anwyl RS, McCoy CB. Possible role of marijuana smoking as a carcinogen in the development of lung cancer at a young age. Journal of psychoactive drugs. 1994 Jul-Sep:26(3):285-8
[PubMed PMID: 7844658]
[46]
Jampel H. American glaucoma society position statement: marijuana and the treatment of glaucoma. Journal of glaucoma. 2010 Feb:19(2):75-6. doi: 10.1097/IJG.0b013e3181d12e39. Epub
[PubMed PMID: 20160576]
[47]
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology (Chicago, Ill. : 1960). 2002 Oct:120(10):1268-79
[PubMed PMID: 12365904]